10 Best Biotech Accelerators and Incubators in 2026 (With Funding)

Last updated: March 2026

A biotech startup accelerator is a fixed-term program that provides life sciences companies with wet lab access, scientific mentorship, investor networks, and seed funding — solving the unique challenges biotech founders face compared to software startups. Biotech ventures need $500K+ for lab equipment, face 10-15 year FDA timelines, and struggle to find investors who understand long development cycles. The right accelerator or incubator can compress years off this timeline.

Peony (free, $0) helps biotech founders share sensitive scientific data, IP documentation, and regulatory materials with investors and accelerator mentors securely. Create branded data rooms in under 5 minutes, protect proprietary research with dynamic watermarks and screenshot protection, and track investor engagement with page-level analytics. Pricing starts free ($0, 2 GB) with Pro at $20/user/month and Business at $40/user/month.

TL;DR: IndieBio for overall best ($250K-$525K + wet labs, 300+ companies funded). JLABS for no-equity lab space (826+ companies incubated globally). StartX Med for Stanford-affiliated equity-free acceleration. BioLabs for flexible multi-city labs (15+ locations, $2,200/bench/mo). Alchemist for B2B biotech.

Biotech Accelerator and Incubator Comparison (2026)

Biotech startups raised $28.4B in 2024 — but 73% fail within 5 years. Specialized accelerators and incubators dramatically improve the odds by providing $2M+ wet lab facilities, scientific mentorship from FDA veterans, biotech investor networks, and equipment sharing that cuts costs by 60-80%. IndieBio alumni alone have raised over $3.2B in follow-on capital.

Here are the 10 best biotech accelerators and incubators in 2026.

Leading Biotech Accelerators and Incubators Worldwide

1. IndieBio (SOSV) — Best Overall Biotech Accelerator

Website: https://indiebio.co Locations: San Francisco, New York Program Duration: 4 months Investment: $250K initial (6-8% equity) + $250K Genesis Consortium SAFE ($6M cap) = up to $525K total

The world's foremost life science accelerator. IndieBio has funded 300+ companies working on cancer therapeutics, sustainable food production, synthetic biology, and diagnostics. Part of SOSV ($1.5B AUM, 961 companies), IndieBio alumni have raised over $3.2B in follow-on capital. Portfolio includes unicorns NotCo ($1.5B valuation) and UPSIDE Foods (formerly Memphis Meats).

What makes them exceptional:

• Funding structure: $250K upfront for 6-8% equity, plus a milestone-based $250K SAFE via the Genesis Consortium (Mayfield partnership) at a $6M valuation cap — totaling up to $525K
• BSL-2 wet labs: Fully equipped labs in SF and NYC with specialized equipment worth millions
• Proven exits: NotCo ($1.5B, Series D), UPSIDE Foods, Chronomics, Prellis Biologics, Wildtype, The EVERY Company
• Follow-on capital: SOSV exercises pro-rata rights at Series Seed, typically investing $250K-$500K additionally
• New York expansion: GP Deborah Zajac leads IndieBio NY with 80 startups and $180M+ in follow-on funding

2025-2026 signals:

• Genesis Consortium III launched in 2025, providing additional capital to top-performing portfolio companies
• SOSV closed Fund V at $306M (2024), strengthening follow-on capacity
• IndieBio aims for ~10% ownership by Series Seed across its portfolio

Best for: Early-stage biotech companies with novel scientific approaches looking for comprehensive lab infrastructure, mentorship, and meaningful seed capital

Application requirements: Novel mechanism (not incremental), proof-of-concept data, PhD-level team, clear path to commercialization

2. Johnson & Johnson Innovation — JLABS — Best for No-Equity Support

Website: https://jnjinnovation.com/jlabs Locations: San Diego, South San Francisco, Boston, New York, Houston, Toronto, Shanghai, Singapore, Korea, and more Program Duration: Rolling admission, 12-18 month typical stays Investment: No equity taken

The world's largest no-equity life sciences incubator. JLABS has incubated 826+ companies globally without taking ownership — including 185+ in APAC alone. J&J's corporate venture arm (JJDC) has separately backed 130 companies, producing 17 IPOs and 54 acquisitions, but JLABS program participation carries zero obligation.

What makes them exceptional:

• Zero equity: Access to world-class facilities and J&J's network without giving up ownership
• Scale: 826+ portfolio companies across 10+ global locations — the largest biotech incubator network
• Strategic access: Connections to J&J's therapeutic areas, regulatory expertise, and commercial channels — without obligation
• Flexible terms: Month-to-month agreements, no forced graduations
• Global reach: Locations span the US, Canada, China, Singapore, and Korea

2025-2026 signals:

• Latest investment: EXoPERT (November 2025) via the incubator program
• APAC expansion: 185+ companies incubated across Shanghai, Singapore, and Korea locations
• JJDC track record: 1 unicorn, 17 IPOs, 54 acquisitions from 130 portfolio companies

Best for: Biotech startups at any stage seeking infrastructure without dilution, companies needing flexible global lab space

Application requirements: Scientific rigor, clear commercial potential, team with relevant experience

3. StartX Med — Best for Stanford-Affiliated Founders

Website: https://startx.com Location: Stanford, California Program Duration: 6+ months Investment: Equity-free (StartX Fund may invest separately)

Stanford-affiliated, equity-free accelerator supporting medical, biotech, and device startups. Known for high alumni success rates with FDA approvals and significant funding rounds.

What makes them exceptional:

• Stanford ecosystem: Deep connections to Stanford research, faculty, and alumni network
• Equity-free acceleration: No equity required for participation (though StartX Fund may invest separately)
• Impressive outcomes: Alumni have raised billions in follow-on funding
• Long-term support: Lifetime access to network and resources
• Selective: Only accepts ~10% of applicants, ensuring high-quality cohorts

Notable alumni: Vir Biotechnology (NASDAQ: VIR), Grail, Notable Health, Freenome

Best for: Stanford-affiliated founders (students, alumni, faculty) working on biotech or medical device innovations

Application requirements: Stanford affiliation, innovative technology, strong team

4. QB3 (UC Berkeley/San Francisco/Santa Cruz) — Best for UC System Entrepreneurs

Website: https://qb3.org Locations: Berkeley, San Francisco, Santa Cruz Program Duration: Varies by program (Early-Stage Mentoring has 3 application windows/year) Investment: Program-dependent

The California Institute for Quantitative Biosciences connects over 200 laboratories across three UC campuses with commercial opportunities. QB3-affiliated companies raised $942 million in 2022 alone. The institute operates the QB3 Garage@Berkeley (Stanley Hall) and the Bakar BioEnginuity Hub — providing wet lab infrastructure to early-stage teams.

What makes them exceptional:

• UC ecosystem: Access to 200+ research labs across Berkeley, UCSF, and Santa Cruz
• Incubator infrastructure: QB3 Garage@Berkeley and Bakar Labs provide subsidized wet lab space
• Research translation: Direct pipeline from UC research to commercialization
• Early-Stage Mentoring: Structured program with 2026 application deadlines (February, May, October)
• Investor network: Strong connections to Bay Area life sciences VCs; regular "4x4" pitch sessions with shared-carry VC funds

Best for: UC-affiliated researchers and entrepreneurs, academic spin-outs needing subsidized lab space and commercialization support

5. Alchemist Accelerator — Best for B2B Biotech and Deep Tech

Website: https://alchemistaccelerator.com Locations: San Francisco, Chicago (quantum/deep tech), Doha (MENA) Program Duration: 6 months Investment: $36K-$50K for ~5% equity

A deep-tech accelerator where 50%+ of alumni close institutional rounds within 12 months of Demo Day. Alchemist focuses exclusively on enterprise/B2B companies — if your biotech has a B2B model (research tools, diagnostic platforms, lab equipment), Alchemist's corporate buyer network converts to revenue faster than generalist programs.

What makes them exceptional:

• Enterprise conversion: 50%+ close institutional funding within 12 months post-Demo Day
• B2B focus: Every mentor and advisor thinks in enterprise terms — ideal for biotech tools and diagnostics
• Investor network: 250+ investor partners, strong connections to corporate buyers
• Geographic expansion: Chicago program (University of Chicago partnership) for quantum/deep tech ($50K per startup), Doha program for MENA enterprise tech

2025-2026 signals:

• Alchemist Chicago launched in partnership with University of Chicago — $50K per startup, 8-10 per cohort, focused on quantum and deep tech
• Alchemist Doha launched with QRDI Council (Qatar) for MENA-focused enterprise tech
• January 2026 class now underway in San Francisco

Best for: Biotech companies with B2B models — research tools, diagnostic platforms, lab automation, enterprise life sciences software

6. AlphaLab Health — Best for Medtech and Pittsburgh Region

Website: https://alphalabhealth.org Location: Pittsburgh, Pennsylvania Program Duration: 12-18 months Investment: Up to $50,000 (backed by $10M evergreen fund)

A Pittsburgh-based accelerator created by Innovation Works, offering funding, mentorship, and prototyping support for life sciences and medtech startups. The $10M evergreen fund ensures sustainable, ongoing investment capacity — unlike fixed-fund accelerators that may run dry.

What makes them exceptional:

• UPMC partnership: Direct access to one of America's largest health systems (40+ hospitals, $26B revenue) for clinical validation and pilot programs
• Evergreen model: $10M fund provides sustainable investment without vintage-year pressure
• Prototyping support: Hands-on help with medical device development, regulatory submissions, and diagnostic platform iteration
• FDA pathway support: Experienced mentors guide regulatory strategy from pre-submission through clearance
• Cost advantage: Pittsburgh operating costs are 40-60% lower than Bay Area or Boston

Best for: Medtech, diagnostic, and digital health startups seeking hospital system access for clinical validation at lower operating costs

Pro Tip: After getting accepted to an accelerator, use Peony to create professional data rooms that showcase your scientific progress, regulatory milestones, and team credentials. AI-powered organization helps structure complex biotech documents, while engagement analytics shows which investors are most interested in your technology.

7. Berkeley Biolabs (Foundry @ CITRIS) — Best for Berkeley Ecosystem

Website: https://foundry.citris.berkeley.edu Location: Berkeley, California Program Duration: Flexible Investment: Lab space and resources (terms vary)

Part of UC Berkeley's innovation ecosystem, providing both incubator and accelerator environments for biotech entrepreneurs. Connected to the CITRIS (Center for Information Technology Research in the Interest of Society) network and 500,000+ Berkeley alumni.

What makes them exceptional:

• Berkeley research access: Collaborate with world-class faculty and researchers across biology, chemistry, and engineering departments
• Flexible programs: Both incubator and accelerator tracks, adaptable to company stage
• Wet lab infrastructure: Lab space in the heart of Berkeley, minutes from campus
• CITRIS ecosystem: Part of a larger innovation network spanning UC Berkeley, UC Davis, UC Merced, and UC Santa Cruz
• Talent pipeline: Direct access to Berkeley graduate students and postdocs for recruiting

Best for: Berkeley-connected founders, companies needing academic collaboration, startups at the intersection of biology and engineering

8. HighTechXL — Best for European Deep Science

Website: https://hightechxl.com Location: Eindhoven, Netherlands Program Duration: 6-12 months Investment: Venture building model (equity varies by involvement level)

The leading European deep-tech venture builder, based in Eindhoven alongside ASML, Philips, and NXP. HighTechXL specializes in building companies from deep science — not just accelerating existing ones. The venture building model means higher equity but significantly more hands-on support, including team assembly and go-to-market strategy.

What makes them exceptional:

• European research pipeline: Direct connections to TU Eindhoven, TNO, and Brainport region research institutions
• Venture building model: Assembles teams, validates technology, and builds companies from scratch — more involved than traditional acceleration
• Corporate ecosystem: Proximity to ASML, Philips, NXP, and other deep-tech corporates for partnerships and pilot programs
• EU funding access: Connections to Horizon Europe, EIC Accelerator, and national grant programs
• Brainport region: Eindhoven is Europe's most patent-dense region per capita

Best for: European founders, researchers with commercializable deep science, teams seeking hands-on venture building rather than light-touch mentorship

9. BioLabs — Best for Multi-City and Global Presence

Website: https://biolabs.io Locations: Boston, Cambridge, New Haven, NYC, Princeton, Philadelphia, Raleigh-Durham, Dallas, San Diego, LA, San Carlos, Paris, Paris-Saclay, Heidelberg, Berlin, Munich (TUM), Kawasaki, Tokyo Program Duration: Flexible membership model Investment: No equity — bench fees from $2,200/month

BioLabs has grown from a single Boston location to 15+ sites globally — the largest flexible lab space network for biotech startups. Founded in 2009, the company expanded aggressively into Europe and Japan in 2025-2026, covering the US, France, Germany, and Japan.

What makes them exceptional:

• Global footprint: 15+ locations across 4 countries, covering every major biotech hub
• Flexible pricing: Single benches ($2,200/mo) to private graduate suites (23 benches) — no long-term lock-in
• No equity: Access infrastructure at bench fees, not ownership stakes
• Specialized facilities: New Philadelphia location rebranded as "BioLabs for Advanced Therapeutics" (March 2025) with dedicated therapeutic development infrastructure
• Japan expansion: Tokyo office established in 2026, Kawasaki facility for APAC-focused startups

2025-2026 signals:

• New 100,000 sq ft San Carlos campus (May 2025), their largest facility
• Philadelphia expansion and rebrand to BioLabs for Advanced Therapeutics
• Tokyo office opened via JETRO partnership (2026)
• European network: Paris, Paris-Saclay, Heidelberg, Berlin, Munich (BioLabs TUM)

Best for: Companies needing flexible lab space across multiple cities, international teams, startups scaling from bench to private suites

10. University Biotech Incubators — Best for Academic Spin-Outs

Examples: bwtech@UMBC, University of Washington CoMotion Labs, Cornell Tech
Locations: Various university campuses
Program Duration: Varies
Investment: Program-dependent

Many universities offer biotech-specific incubators providing wet lab space, office infrastructure, and academic collaboration for early-stage life sciences companies spinning out of university research.

What makes them exceptional:

• Technology transfer support: Help navigating IP and licensing from universities
• Academic collaboration: Continued access to university researchers and equipment
• Talent pipeline: Easy recruiting from student and postdoc populations
• Affordable: Often subsidized rates for lab space
• Local ecosystem: Integration with regional biotech communities

Best for: Companies spinning out of academic research, early-stage teams needing basic infrastructure

Choosing the Right Biotech Accelerator

Not all accelerators fit all companies. Consider these factors:

Stage and Maturity

• Idea stage: University incubators or equity-free programs like JLABS
• Early prototype: IndieBio, Alchemist, QB3
• Growth stage: BioLabs for flexible space as you scale
• Academic spin-out: StartX Med (Stanford), QB3 (UC), university-specific programs

Geographic Considerations

Major biotech hubs have unique strengths:

• San Francisco Bay Area: Largest concentration of biotech VCs and talent — IndieBio (SF, NYC), QB3 (Berkeley), Berkeley Biolabs, BioLabs (SF, San Carlos)
• Boston/Cambridge: Strong academic institutions (MIT, Harvard), established pharma presence — JLABS, BioLabs (Boston, Cambridge, New Haven)
• San Diego: Growing ecosystem with JLABS and BioLabs locations
• Research Triangle (NC): Lower costs, strong universities — BioLabs (Raleigh-Durham)
• Pittsburgh: Emerging hub with UPMC partnership — AlphaLab Health ($10M fund, 40-60% lower operating costs than coasts)
• Europe: HighTechXL (Eindhoven), BioLabs (Paris, Heidelberg, Berlin, Munich), CDL Health (Oxford, Imperial College)
• Asia-Pacific: JLABS (Shanghai, Singapore, Korea), BioLabs (Tokyo, Kawasaki)

Technology Focus

Some accelerators specialize:

• Therapeutics: IndieBio, JLABS, StartX Med
• Medical devices: AlphaLab Health, university programs
• Diagnostics: Most accelerators support, but validate market access support
• Synthetic biology: IndieBio excels here
• Digital health: Some accelerators (AlphaLab Health) blend biotech and software

Equity Considerations

Equity models vary significantly:

• No equity: JLABS (826+ companies, $0), BioLabs ($2,200+/bench/mo), CDL (zero-fee, zero-equity)
• Equity-free acceleration: StartX Med (though StartX Fund may invest separately)
• Standard equity: IndieBio (6-8% for $250K + $250K SAFE), Alchemist (~5% for $36K-$50K)
• Venture building: HighTechXL (higher equity for more hands-on company building)

Consider how much dilution you're comfortable with at this stage. IndieBio's $525K total at 6-8% is competitive for a program that includes BSL-2 wet lab access.

Resources Needed

What do you need most?

• Wet lab space: IndieBio (BSL-2, SF/NYC), JLABS (10+ global locations), QB3 (Berkeley/UCSF), BioLabs (15+ sites, $2,200+/bench)
• Funding: IndieBio ($250K-$525K), AlphaLab Health (up to $50K), Alchemist ($36K-$50K)
• Mentorship: All provide, but verify mentor quality — IndieBio's Genesis Consortium pairs alumni with Mayfield partners
• Investor network: IndieBio ($3.2B+ in alumni follow-on), Alchemist (250+ investor partners, 50%+ close in 12mo)
• Academic collaboration: QB3 (200+ UC labs), Berkeley Biolabs (CITRIS network), StartX Med (Stanford)
• Corporate partnerships: JLABS (J&J therapeutic access), AlphaLab Health (UPMC, 40+ hospitals)

Applying to Biotech Accelerators

Increase your chances of acceptance with these strategies:

Build a Strong Scientific Foundation

Accelerators look for:

• Novel mechanism or approach: Not incremental improvements
• Proof of concept data: Even preliminary results showing your hypothesis works
• Clear differentiation: Why your approach beats existing solutions
• Validated target: Evidence the biological target is relevant to disease
• Freedom to operate: No obvious blocking IP issues

Assemble the Right Team

Biotech requires multidisciplinary expertise:

• Scientific founder(s): PhD-level expertise in relevant area
• Business/operations: Someone who understands commercialization
• Complementary skills: Chemistry + biology, research + clinical, etc.
• Track record: Prior publications, patents, or startup experience
• Commitment: Full-time or clear path to full-time

Articulate Commercial Potential

Science alone isn't enough. Show:

• Market size: Large enough to interest investors (typically $1B+ TAM)
• Clear path to revenue: How you'll make money (partnerships, product sales, licensing)
• Competitive landscape: Who else is working on this, why you'll win
• Development timeline: Realistic milestones to key value inflection points
• Funding strategy: How much capital needed, what it accomplishes

Prepare Application Materials

Create polished, professional materials:

• Executive summary: One-page overview of science, team, market, plan
• Pitch deck: 10-15 slides covering problem, solution, science, team, market, ask
• Data package: Scientific data, publications, preliminary results
• Team bios: Highlight relevant expertise and accomplishments
• Development plan: Timeline and milestones for next 12-24 months

After acceptance, use Peony to create professional data rooms for sharing materials with mentors, advisors, and potential investors. Peony's AI-powered organization helps biotech teams structure complex scientific data, regulatory documents, and IP materials logically—critical for biotech fundraising.

Life After the Accelerator: Fundraising for Biotech

Most biotech companies need substantial follow-on funding after accelerators:

Funding Stages and Amounts

• Pre-seed/Seed: $500K-$3M for proof of concept, initial data
• Series A: $5M-$15M for lead optimization, IND-enabling studies
• Series B: $20M-$50M for Phase I/II clinical trials
• Series C+: $50M-$150M+ for Phase III, commercial preparation

Types of Biotech Investors

• Specialized biotech VCs: Top biotech investors with deep scientific expertise
• Corporate venture: Pharma and medtech corporate venture arms
• Non-dilutive funding: NIH SBIR/STTR grants, foundations, government programs
• Strategic partnerships: Pharma partnerships with upfront payments and milestones

Preparing for Investor Due Diligence

Create a comprehensive investor data room with:

• Scientific data: All experimental results, publications, presentations
• IP documentation: Patents (filed and pending), freedom-to-operate analyses
• Regulatory strategy: FDA pathway, preclinical requirements, trial designs
• Financial models: Development costs, funding needs, valuation analysis
• Team information: CVs, advisors, SAB members
• Competitive analysis: Landscape of competing approaches and companies

Peony helps biotech startups create professional, organized data rooms with engagement analytics showing which investors are most interested. Features like dynamic watermarks and screenshot protection protect sensitive scientific data and IP.

Frequently Asked Questions

What is the best biotech startup accelerator in 2026?

IndieBio (SOSV) is the best overall biotech accelerator in 2026. It provides $250K initial investment for 6-8% equity plus an additional $250K via the Genesis Consortium SAFE at a $6M valuation cap — totaling up to $525K. IndieBio operates BSL-2 wet labs in San Francisco and New York, has funded 300+ companies, and its portfolio includes unicorns NotCo ($1.5B) and UPSIDE Foods. For no-equity programs, JLABS (Johnson & Johnson) has incubated 826+ companies globally without taking ownership. Peony (free, $0) helps biotech founders create professional data rooms for investor outreach with page-level analytics and dynamic watermarks to protect sensitive IP.

Which biotech accelerators do not take equity?

JLABS (Johnson & Johnson Innovation) is the largest no-equity biotech incubator with 826+ portfolio companies across 10+ global locations. StartX Med (Stanford-affiliated) provides equity-free acceleration with lifetime access to the Stanford network. BioLabs operates 15+ locations globally with bench fees starting at $2,200/month instead of equity. Creative Destruction Lab runs zero-fee, zero-equity biotech mentorship programs at 16 sites across 10 countries. Peony (free, $0) provides secure data rooms with screenshot protection for sharing sensitive research with these programs.

How much funding do biotech accelerators provide?

Funding ranges from $0 to $525K: IndieBio provides up to $525K total ($250K initial + $250K Genesis SAFE), Alchemist offers $36K-$50K for ~5% equity, and AlphaLab Health provides up to $50K from their $10M evergreen fund. Equity-free programs like JLABS and BioLabs charge membership fees instead of taking ownership. SOSV overall manages $1.5B AUM across 961 companies. After securing accelerator funding, Peony (free, $0) helps create investor data rooms for Series A fundraising with page-level analytics showing which VCs engage most.

What is the difference between a biotech accelerator and incubator?

Biotech accelerators (IndieBio, Alchemist) run fixed-term programs (4-6 months) with structured mentorship, funding, and demo days — IndieBio invests $250K-$525K for equity. Incubators (JLABS, BioLabs, university programs) provide ongoing lab space with flexible timelines — JLABS takes no equity, BioLabs charges bench fees from $2,200/month. Many biotech companies use both: starting in a university incubator for subsidized lab space, joining IndieBio for intensive acceleration and funding, then moving to BioLabs for flexible multi-city lab access as they scale. Peony (free, $0) serves both stages with secure data rooms for investor communications and IP protection.

Related Resources for Biotech Entrepreneurs

Finding Investors

• Top 15 Biotechnology Investors
• Top 15 Agriculture Investors (for ag-bio)
• Top B2B SaaS Investors (for SaaS-biotech crossover)

Other Accelerator Options

• Top 20 Startup Accelerators Worldwide
• Top Startup Accelerators in San Francisco
• Top 10 Canadian Startup Accelerators
• Top Startup Accelerators in Boston
• Top 10 AI Startup Accelerators (for AI-driven biotech)

Fundraising Best Practices

• Due Diligence Cost Breakdown — what investors spend on diligence
• Why Startups Need Data Rooms for Fundraising
• Virtual Data Room Cost Guide
• Biotech Data Rooms

Secure Document Sharing

• Top Secure File Sharing Tools
• Password Protect Video Guide — protect lab presentations

Common Mistakes to Avoid

Learn from others' errors:

1. Underestimating Timeline and Capital Needs

Biotech takes longer and costs more than you think. Build 50% buffers into all estimates. Investors will respect realistic projections more than overly optimistic ones.

2. Ignoring Regulatory Strategy Early

Don't wait until you have a product to think about FDA pathways. Early regulatory strategy informs development decisions and de-risks the program for investors.

3. Weak IP Position

Understand your freedom to operate and file strong patents early. Biotech investors scrutinize IP heavily—it's often the most valuable asset.

4. Poor Data Presentation

Scientific data must be clear, well-organized, and professionally presented. Sloppy data presentation raises questions about scientific rigor. Use professional data rooms to showcase your research professionally.

5. Inadequate Market Understanding

Even great science needs a path to commercialization. Understand market size, payers, competition, and go-to-market strategy.

Final Thoughts

Science-driven startups thrive with credible acceleration—especially when programs offer wet lab access, regulatory guidance, and commercialization networks. The biotech accelerators listed here provide the infrastructure, expertise, and networks that can shave years off development timelines and dramatically increase the probability of success.

Choosing the right accelerator depends on your specific needs: stage, geography, technology focus, and resources required. Many biotech companies participate in multiple programs over their lifecycle—perhaps starting in a university incubator, graduating to IndieBio or JLABS for intensive acceleration, then moving to BioLabs for flexible space as they scale.

After completing accelerator programs, the journey continues with fundraising, partnerships, and clinical development. Professional tools like Peony make document management and investor engagement much smoother. Peony's branded data rooms, AI-powered organization, and engagement analytics streamline communication with investors, partners, and advisors—helping biotech founders shine while protecting sensitive scientific data and IP.

The path from scientific breakthrough to commercial reality is long and challenging, but with the right accelerator support and tools, biotech entrepreneurs can transform groundbreaking research into therapies, diagnostics, and platforms that improve human health and wellbeing.

Ready to apply to biotech accelerators? Create a professional data room with Peony (free, $0) to showcase your science, team, and vision. Share sensitive IP through branded data rooms with dynamic watermarks, screenshot protection, and page-level analytics — set up in under 5 minutes.